19 December 2023: Original Paper
Allogeneic Hematopoietic Stem Cell Transplantation Can Improve Prognosis of Extramedullary Infiltration Positive t(8;21) Acute Myeloid Leukemia
Xiaokai Wang 1BCDEF* , Xuetong Xu 2BCDF* , Hao Zhang 3CDF* , Wei Zhou 45BC , Dan Gong 6BD , Chengying Zhu 78CF , Dejun Zhou 9ADFG* , Guofeng Chen 9ABCDEFG*DOI: 10.12659/AOT.942197
Ann Transplant 2023; 28:e942197
Table 4 Characteristics of 15 patients who received allo-HSCT.
| No. | Sex (M/F) | Age (years) | Donor | Site of EMI | Cycles of consolidation | Interval* (months) | Disease status** | OS (months) | Outcome | Post-transplant complications |
|---|---|---|---|---|---|---|---|---|---|---|
| N4 | M | 10 | MUD | Liver | 2 | 7.1 | CR1 | 94.9 | Alive | |
| N6 | F | 16 | MUD | Spleen | 6 | 18.2 | CR1 | 67.2 | Alive | |
| N8 | M | 13 | MUD | Orbit | 4 | 13.4 | CR2 | 43.2 | Alive | |
| N23 | F | 47 | MSD | CNS | 3 | 5.8 | CR1 | 21.3 | Dead | Relapse, infect |
| N24 | F | 24 | HID | Multiple | 3 | 7.1 | CR1 | 32.8 | Dead | Infect |
| N29 | M | 7 | HID | CNS | 1 | 10.6 | NR | 20.5 | Dead | Relapse |
| N30 | M | 21 | MUD | Multiple | 7 | 17.1 | NR | 19.7 | Dead | Respiratory failure, infect |
| N31 | M | 42 | MSD | Multiple | 3 | 5.3 | CR1 | 13.3 | Dead | cGVHD |
| N40 | F | 12 | HID | Multiple | 1 | 4.0 | CR1 | 16.6 | Alive | |
| N43 | M | 27 | MUD | Bone | 3 | 5.9 | CR1 | 7.9 | Dead | Heart failure, liver failure |
| N44 | F | 23 | MSD | Skin | 3 | 4.4 | CR1 | 91.5 | Alive | |
| N45 | M | 8 | MSD | Multiple | 1 | 14.9 | CR2 | 136.9 | Alive | |
| N47 | F | 29 | MSD | Skin | 0 | 2.6 | CR1 | 84.1 | Alive | |
| N50 | M | 13 | MSD | CNS | 2 | 3.6 | CR1 | 35.9 | Dead | |
| N51 | M | 39 | MSD | Lymph nodes | 0 | 4.6 | CR1 | 49.2 | Alive | |
| * Interval between diagnosis and transplantation; ** disease status at transplantation. Allo-HSCT – allogeneic hematopoietic stem cell transplantation; M – male; F – female; MSD – matched sibling donor; MUD – matched unrelated donor; HID – haploidentical donor; EMI – extramedullary infiltration; CNS – central nervous system; CR1 – the first complete remission; CR2 – the second complete remission; NR – none remission; cGVHD – chronic graft-versus-host disease. | ||||||||||